Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses: Erratum

In an article published in the November-December 2022 issue of the Journal of Clinical Psycopharmacology,¹ a unit of measure was incorrectly reported in the Results section of the Abstract. Instead of “mg/dL” the text should have referred to “ng/dL.” The correct sentence is:

“A clozapine TDM value above the therapeutic range (>600 ng/dL) was associated with a high risk of QTPP status (adjusted odds ratio, 6.5; 95% confidence interval, 1.7–25.2; P = 0.006).”

Additionally, the wording could have been more precise about how clozapine was measured in the reported research. In this research, clozapine concentration in serum was measured. Therefore, in the article title and several places in the article, the wording of “clozapine serum concentration” should have been used rather than “clozapine blood concentration” or “plasma clozapine concentration.”